title: [Efficiency and safety of human monoclonal antibodies to TNF-alpha in children with juvenile idiopathic arthritis in primary and secondary ineffectiveness of other biologicals].
abstract: OBJECTIVE
  To evaluate the safety and efficiency of adalimumab in children with severe refractory JIA with primary inefficiency, partial effect or loss of the effectiveness of other biologicals.
  
  
  METHODS
  The article presents the results of the retrospective observational study of the efficacy and safety of adalimumab in 68 patients aged 10 (3, 17) years with various embodiments of JIA, with the primary inefficiency or partial or loss of the effectiveness of other biologicals. JIA diagnosis established on the basis of criteria ILAR (International League of Associations for Rheumatology).
  
  
  RESULTS
  Efficacy was assessed during 1 year in 68 and 2 years--in 56 patients . At the 24th week we observed the improvement by criteria AKR 30, 50.70 in 100, 91 and 74% of patients, respectively, and at the 52th week--in 100, 96 and 90%, respectively. Inactive disease status was recorded in 55.8, 66.1 and 98.2% of study participants after 6 months, 1 and 2 years, respectively. Remission was achieved in 55.8 and 96.4% of patients after 1 and 2 years of observation, respectively.
  
  
  CONCLUSIONS
  Adalimumab was effective and well tolerated by patients with primary inefficiency, partial and loss of efficiency of other biologicals. In clinical practice, patients with non-systemic JIA transition to the second TNF-alpha blocker can restore the biological effect of the first drug without increasing the frequency of infectious AEs.
authors.forename: E I
authors.initials: EI
authors.lastname: Alekseeva
authors.forename: A A
authors.initials: AA
authors.lastname: Baranov
authors.forename: E V
authors.initials: EV
authors.lastname: Mitenko
authors.forename: T M
authors.initials: TM
authors.lastname: Bzarova
authors.forename: S I
authors.initials: SI
authors.lastname: Valieva
authors.forename: R V
authors.initials: RV
authors.lastname: Denisova
authors.forename: K B
authors.initials: KB
authors.lastname: Isaeva
authors.forename: E G
authors.initials: EG
authors.lastname: Chistiakova
authors.forename: T V
authors.initials: TV
authors.lastname: Sleptsova
authors.forename: N I
authors.initials: NI
authors.lastname: Taĭbulatov
authors.forename: E I
authors.initials: EI
authors.lastname: Zelikovich
authors.forename: G V
authors.initials: GV
authors.lastname: Kurilenkov
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001685:Biological Factors / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D001685:Biological Factors; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab